| Trial ID: | L3091 |
| Source ID: | NCT01784965
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01784965/results
|
| Conditions: |
Pre-diabetes|Older Adults
|
| Interventions: |
DRUG: liraglutide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Weight Reported at 14 Weeks, Change in weight with caloric restriction plus liraglutide vs. caloric restriction and placebo over 14 weeks., Baseline and 14 weeks | Secondary: Glucose-stimulated Insulin Secretion in Insulin AUC, Pmol/1x 4H, Absolute change in glucose-stimulated insulin secretion (GS-IS) associated with caloric restriction plus liraglutide vs. caloric restriction and placebo at 14 weeks, Baseline, 14 weeks|Insulin Resistance in the Liraglutide vs.Placebo Group After Calorie Restriction, Mean (+/- SD) change in insulin resistance associated with caloric restriction plus liraglutide vs. caloric restriction and placebo., Baseline, 14 weeks
|
| Sponsor/Collaborators: |
Sponsor: Stanford University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
69
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2009-12
|
| Completion Date: |
2012-12
|
| Results First Posted: |
2017-04-21
|
| Last Update Posted: |
2017-04-21
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01784965
|
